

Case study

**ROLE OF RADIOTHERAPY IN RECURRENT MALIGNANT MELANOMA OF THE EYELID
A CASE REPORT AND REVIEW OF LITERATURE**

ABSTRACT:

Malignant Melanoma of the eyelid skin arises from the abnormal proliferation of melanocytes. It is a rare condition that accounts for < 1% of all melanomas. They are usually a result of DNA damage from exposure to UVB (290-320). Other common risk factors include Fair skin, red/blond hair, high-density freckling, light eyes (green/ hazel/blue), family history of melanoma or dysplastic nevi, immunosuppression (congenital or acquired), UVA (tanning beds, PUVA therapy). Mutations in CDKN2A, CDK4, XP, BRCA2 genes occurs in 10% of the melanoma.¹ Lower eyelid is the most common location of the eyelid melanoma, where it is approximately 2.6 times more likely to occur than the upper eyelid. Here we present a rare case of recurrent eyelid melanoma in a 62-year-old lady.

KEYWORDS: Nevi, Malignant melanoma, Metastasis, Upper eyelid, Radiotherapy.

INTRODUCTION

Ocular melanoma, which is much less common than cutaneous melanoma and arises from a variety of tissues, including the uvea, conjunctiva, eyelid, orbit, and lacrimal sac, differs from other forms of melanoma in terms of the characteristics of the patient, the symptoms of the illness, and the prognosis [1]. The most common histological subtype is "Lentigo maligna melanoma." Since it is exposed to more sunlight, the lower eyelid is more frequently affected. Surgery is the main form of treatment for eyelid melanoma (EM), and among the reconstruction techniques are direct closure, full thickness skin grafting, local/regional, or free flaps [2,3]. The most popular technique for preserving the globe is radiation therapy, which comprises External Beam Radiotherapy, Brachytherapy, Proton beam therapy, stereotactic radiosurgery, and stereotactic radiotherapy [4]. If applied as directed, all forms of radiation have good local cancer control and eye preservation rates [5,6]. Chances of Recurrence in Eyelid Melanomas are high. The likelihood of treatment failure increased with increasing age, tumour thickness, basal size, and proximity to the foveal avascular zone [7,8]. Most recurrences occur along the posterior edge of the tumour [9]. The first two years are when recurrences are most frequently noticed, while the subsequent five years see relatively less [10]. Recurrence and the development of metastatic disease have been reported [11]. Herein we describe a rare case of recurrent eyelid melanoma in a 62-year-old lady.

CASE REPORT:

A 62-year-old female patient known case of Malignant Melanoma Eyelid presented to our department with complaints of a multiple nodules under the upper eyelid with history of decreased vision and continuous watering in right eye. On examination, a nodule measuring 1x1cm noted near the inner canthus of right eye in the upper eyelid, hard in consistency, mobile, eye movements being restricted. Two sub-centimetric nodules noted in upper eyelid, mobile, non-tender. Irregularity in right bulbar conjunctiva noted. **(Fig-1)**. Enlarged lymph node in right pre auricular region measuring 1x1cm, hard in consistency, fixed, tender.

She had a past history of pigmented growth in the lower bulbar conjunctiva **(Fig-2)** 2 years ago, was evaluated outside and underwent excision for the same. Histopathological examination showed melanoma. Patient presented with swelling in the right lower eyelid, 3 weeks after the excision. Map biopsy was done and was started on injection mitomycin C 0.04% as adjuvant therapy. She was lost to follow up.

Present PET CT showed FDG avid nodular enhancing lesion in right upper eyelid, extending for a length of about 2.8cms with maximum thickness of 1cm, SUV:7.1. FDG avid enlarged enhancing right intraparotid node is seen measuring 1.3x1cm with SUV: 11.5. She underwent right orbital exenteration with superficial parotidectomy and type III modified radical neck dissection with split skin grafting. Post operative histopathological examination revealed as malignant melanoma, epithelioid cell type. Intraparotid lymph node positive for metastatic deposit with Extranodal extension. 1/18 was positive for metastatic deposit. Pathological staging PT4aN2M0 (Stage IIIC). She was planned for adjuvant radiation therapy and she received 60 Gy in 30 fractions to primary, 66 Gy in 30 fractions to the right parotid bed and 54 Gy in 30 fractions to ipsilateral neck nodes from level I to level V. **(Fig-3)** She completed the treatment uneventfully. Her vision in left eye was maintained post radiation therapy. Patient was referred for an ocular prosthesis post radiation therapy for proper cosmetic outcome.



Fig-1 showing nodules in upper eyelid and thickening in bulbar conjunctiva

Fig-2 showing pigmented growth in the lower bulbar conjunctiva




Fig-3 Showing the radiation target volumes and coverage

DISCUSSION:

Most common subtype of melanoma is superficial spreading, which makes up 70% of malignant melanoma cases [12]. These are typically brought on by exposure to the sun and affect the trunk and/or extremities. Nodular subtype melanoma accounts for 15% to 30% of cases [12]. The lentigo maligna subtype usually presents as macules that resemble freckles in older adults who has a history of UV exposure [13]. The least common melanoma subtype, acral lentiginous melanoma, only accounts for fewer than 5% of cases. This variety appears to be more prevalent in patients with dark skin tones and Asian ancestry, and it most usually affects the palms and soles. Mucosal melanoma makes up only 1% of all occurrences of melanoma, which is incredibly rare [14]. They typically appear in the head and neck, anorectum, vagina, and vulva [15].

People at high risk, such as those with a propensity for melanoma in their families or a history of numerous clinically abnormal moles, are advised to regularly self-examine their skin and follow up once per year, according to the American Academy of Dermatology (AAD). Key screening criteria for the ABCDE system include asymmetry, border irregularities, colour variation (different colours in the same region), diameter >6 mm, enlargement or evolution of colour change, shape, or symptoms. People with a family history should consider getting genetic counselling [16].

Surgery is the primary method of melanoma treatment. It is recommended to carry out a broad local excision, with the necessary margin depending on the thickness of the tumour. Sentinel lymph node (SLN) status is the most important predictive factor for recurrence in melanoma patients. It is recommended that patients have SLNB if their thickness is less than or equal to 0.75 mm and they exhibit any high-risk characteristics (ulceration, LVSI, or mitotic rate greater than or equal to 1/mm²). Complete lymphadenectomy is indicated for patients with positive SLNB since 18% of people with positive SLN will also have other lymph nodes spread [17,18].

Locally advanced Melanoma patients with resected node-positive typically get high-dose IFN consistently for a year. The role of immunotherapy in adjuvant situations is evolving. Based on the results of EORTC 18071, which demonstrated that using ipilimumab adjuvantly was superior to using a placebo for recurrence-free survival [19]. Ipilimumab therapy is now categorised as a category 1 treatment option by NCCN following resection of clinical stage III disease. Vemurafenib, a medication that specifically inhibits the BRAF V600 mutation, which is present in 40% to 60% of those with metastatic melanoma. Dabrafenib and trametinib (an MEK inhibitor), which are also approved for use in BRAF-mutated metastatic melanoma, are other treatment options. Pembrolizumab and Nivolumab which are anti-PD-1 inhibitors are being used more and more to treat melanoma.[20,21].

In cases where surgery could leave patients with deformity, definitive radiation therapy is used. Candidates for RT alone include patients with superficial lentigo maligna (limited to epidermis) and lentigo maligna melanoma (invasive into dermis). These patients are typically elderly and may have extensive superficial lesions on the face. Nonsurgical methods may provide better function and cosmesis [22]. 50 Gy in 20 fractions with the appropriate energy electrons are reasonable [23]. Adjuvant radiation therapy is indicated for the treatment of primary tumour beds in melanomas with desmoplastic or neurotropic features, as well as thick lesions (>4 mm). Adjuvant radiation can be used to treat positive margins. Potential criteria for treating regional lymph nodes include multiple positive lymph nodes, extra capsular extension, lymph nodes 3 to 4 cm in size, involvement of the sentinel lymph node without full or adequate lymph node dissection, and recurrent illness [24]. The fractionation schedules that are most widely used are Hypo-fractionation. With a remarkable 10-year local control rate, hypo-fractionated RT (30 Gy/5 fractions) is a safe and effective adjuvant therapy for melanoma. [25,26]. In order to prevent local recurrence of high-risk melanoma and recurrent melanoma of the eyelids, we advise considering adjuvant radiation.

CONCLUSION:

Early detection of eyelid malignant melanoma is crucial to preventing potentially deadly outcomes, which have been recorded in multiple cases, especially when the cancer is growing on an existing nevus. We recommend radiation in adjuvant settings to reduce the local recurrence of eyelid melanoma.

Consent

As per international standard or university standard, patient(s) written consent has been collected and preserved by the author(s).

Ethical Approval:

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

REFERENCES:

1. Chang A.E., Karnell L.H., Menck H.R. The national cancer data base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer*. 1998;83:1664–1678.
2. American Cancer Society—Melanoma. 2017. <http://old.cancer.org/cancer/analancer/detailedguide/anal-cancer-what-is-anal-cancer>, 2017.
3. Ogawa T, Nakayama B, Hasegawa Y, et al. Treatment of malignant melanoma of the lower eyelid using anterolateral thigh flap. *Auris Nasus Larynx* 2000; 27:79–82.
4. Foti, P.V.; Travali, M.; Farina, R.; Palmucci, S.; Spatola, C.; Liardo, R.L.E.; Milazzotto, R.; Raffaele, L.; Salamone, V.; Caltabiano, R.; et al. Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part II: Treatment indications and complications. *Insights Into Imaging* **2021**, *12*, 67.
5. Sarici, A.M.; Pazarli, H. Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma. *Graefe's Arch. Clin. Exp. Ophthalmol.* **2012**, *251*, 285–294.
6. Verma, V.; Mehta, M. Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma. *Clin. Oncol.* **2016**, *28*, e17–e27.
7. Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, Diddie KR, Engstrom RE Jr, Finger PT, Hovland KR, Joffe L, Olsen KR, Wells CG; Collaborative Ocular Melanoma Study Group (COMS Group): The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, IV: local treatment failure and enucleation in the first 5 years after brachytherapy: COMS report No. 19. *Ophthalmology* 2002;109:2197-2206.
8. Quivey JM, Char DH, Philips TL, Weaver KA, Castro JR, Kroll SM: High intensity 125-iodine (125I) plaque treatment of uveal melanoma. *Int J Radiat Oncol Biol Phys* 1993;26:613-618.
9. Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, Brady LW: Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. *Arch Ophthalmol* 2002;120:933-940.

10. Char DH, Kroll S, Phillips TL, Quivey JM: Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. *Ophthalmology* 2002;109:1850-1854.
11. Gallie BL, Simpson R, Saakyan S, Amiryan A, Valskiy V, Finger PT, Chin KJ, Semenova E, Seregard S, Fili M, Wilson M, Haik B, Caminal JM, Català J, Gutierrez C, Pelayes DE, Folgar AM, Jager MJ, Dogrusöz M, Luyten GPM, Singh A, Schachat AP, Suzuki S, Aihara Y; The Ophthalmic Oncology Task Force: Local recurrence significantly increases the risk of metastatic uveal melanoma. *Ophthalmology* 2016;123:86-91.
12. Wolff K, Goldsmith L, Katz S, et al. *Fitzpatrick's Dermatology in General Medicine*. 7th ed. New York, NY: McGraw-Hill; 2008:1134.
13. Clark WH, Jr., Mihm MC, Jr. Lentigo maligna and lentigo-maligna melanoma. *Am J Pathol*. 1969;55(1):39-67.
14. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer*. 1998;83(8):1664-1678.
15. Hajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. *Int J Clin Exp Pathol*. 2012;5(8):739-753.
16. www.aad.org
17. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in Stage IB and II melanoma patients: two-step prognostic indicators of survival. *J Clin Oncol*. 2006;24(27):4464-4471.
18. Lee JH, Essner R, Torisu-Itakura H, Wanek L, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. *J Clin Oncol*. 2004;22(18):3677-3684.
19. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2015;16(5):522-530.
20. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med*. 2015;372(1):30-39.
21. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med*. 2014;371(20):1877-1888.
22. Hendrickx, A., Cozzio, A., Plasswilm, L. *et al.* Radiotherapy for lentigo maligna and lentigo maligna melanoma – a systematic review. *Radiat Oncol* **15**, 174 (2020). <https://doi.org/10.1186/s13014-020-01615-2>
23. Fogarty GB, Hong A, Scolyer RA, Lin E, Haydu L, Guitera P, Thompson J. *Br J Dermatol*. 2014 Jan;170(1):52-8.
24. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in Stage IB and II melanoma patients: two-step prognostic indicators of survival. *J Clin Oncol*. 2006;24(27):4464-4471.
25. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant

- melanoma: Trans-Tasman Radiation Oncology Group (TROG) Study 96.06. *Radiother Oncol.* 2006;81(2):136–142.
26. Brady MS. Adjuvant radiation for patients with melanoma. *Lancet Oncol.* 2015;16(9):1003–1004.

UNDER PEER REVIEW